OSCR 全部观点

已加载 4 条观点条目,其中 0 条方向发生变化

在已加载记录中筛选
The Motley Fool发布 2026-11-13
《5 Stocks Set to Soar in 2027》
$OSCR中性
AI 摘要 · Oscar Health的未来方向看起来有前景,但说话者一直未入场,因为华盛顿在ACA及其资金方面的决定——不在公司控制范围内——可能深刻影响其业务并引发波动,而他不知道这些决定将如何收场。他曾考虑建立一个小仓位,在经历一次大幅下跌后可能转为完整仓位;OSCR已列入他2027年的关注名单。

我认为这大概率是未来的方向,对 Oscar Health 是好事。我作为股东唯一无法支持 Oscar Health 的原因,是我在监管环境中看到的风险。

think that's probably the future direction , and it's good for Oscar Health . The only reason I couldn't support Oscar Health as a shareholder is the risks I see in the regulatory landscape.

我只担心立法者可能会做什么,这将对 Oscar Health 的业务产生重大而深远的影响,而这完全不在公司的控制范围内,也就是华盛顿决定怎么做。

I am only concerned about what the legislators might do, which will have a significant and profound impact on Oscar Health's business, and this is something completely out of the company's control, i.e., what Washington decides to do.

他说在等
立法者对《平价医疗法案》资金与支持的决定
对ACA资金与支持的有利决定
2027年之前华盛顿方面关于ACA资金的立法与监管决定
将缓解使他无法投资的监管风险
The Motley Fool发布 2026-11-10
《Stock Market Update: Rising Rates & Falling Stocks》
$OSCR看涨
AI 摘要 · OSCR又交出一个好季度并上调全年指引:收入从187–190亿美元上调至190–193亿美元,经营利润展望上调,医疗赔付率预计为80.5–81.5%;管理层称正朝着最强财年迈进,公司盈利且增长迅速。说话者看好OSCR的方向,提到Mark的领导力和有吸引力的ICRA市场模式,但尚未持股,并希望自己在20美元左右买入过。

他们上周确实发布了财报。又是一个相当不错的季度。让我想想我记不记得。我觉得他们可能又上调了指引。对,我觉得展望被上调了。他们现在预计营收在190亿到193亿美元之间,高于此前的187亿到190亿美元。

全年展望中,运营利润也上调了。医疗成本率,医疗赔付率现在预计在80.5到81.5之间,所以这方面略有改善。公司表示,他们有望实现历史上最强的财务表现。他们确实在盈利,而且增长相当快。

They they did report last week. It was another pretty good quarter. Let me see if I can remember. Um I think they they might have raised guidance again. Yeah, I think outlook was was raised.

Um they're now looking at between 19 to 19.3 billion in revenue. That's up from $18.7 to19 billion. Uh earnings from operations is also up for the full full year outlook. Medical cost rat medical loss loss ratio is now expected to be between 80.5 to 81.5.

So slight improvement there. Um co said they're on track to deliver the strongest year of financial performance in their history. They actually generate profit. They're growing quite quickly.

Parkev Tatevosian, CFA发布 2026-09-28
《3 Undervalued Healthcare Stocks Invstors Can Buy Right Now》
$OSCR看涨
AI 摘要 · OSCR 目前被低估,公允价值高于 41 美元,现价约 30 美元,意味着在增长与成本控制推动下,12-18 个月内有超过 34% 的上行空间。

最后但同样重要的是Oscar Health,它是在将人工智能整合到运营中以提升效率和业绩方面最顶尖的医疗保健公司之一。它是自2024年以来增长最快的医疗保健公司之一。它实现了超过40%的复合年收入增长率。

管理层预计,从现在到2030年,复合年收入增长率将超过20%。它正在控制成本,而随着收入和净利润的扩张,利润也在改善。

Last but not least, Oscar Health, one of the top healthcare companies in terms of integrating artificial intelligence into its operations to improve efficiency and performance.

It is one of the fastest growing healthcare companies since 2024. It has achieved a compound annual revenue growth rate of over 40%. Management anticipates compound annual revenue growth rates exceeding 20% from now until 2030.

It is controlling costs, and profits are improving as a result of this expansion in revenue and net profit.

Chip Stock Investor发布 2026-09-03
《Why Oscar Health's 'Great Quarter' Isn't What It Looks Like》
$OSCR看跌
AI 摘要 · OSCR并不便宜,也不值得买入;对保险公司而言,自由现金流具有误导性,因为资金并非永久留存。

Oscar Health,一家健康保险公司,本季度表现非常出色。他们的收入非常可观。他们的订阅用户基础正在增长。自由现金流为正。一切看起来都很好。

Oscar Health, which is a health insurance company, had a really great quarter. They've got fantastic revenue. Their subscriber base is growing. Free cash flow is positive. Everything looks great.

你如何对那家公司进行反向DCF分析?对于这样的公司,你会使用什么终端增长率?这让我们思考如何着手看待这个问题。

How do you run a reverse DCF on that company? What terminal rate would you use for a company like this? And so that got us thinking about how we would go about looking at this.

已经是最早的记录
其他股票的全部观点条目
把 $OSCR 加入我的股票30 天完整试用
开始试用